Safety and tolerability of the new phosphodiesterase inhibitor B9302-107 administered to healthy male volunteers as repeated oral doses over 3 weeks - A double-blind randomized placebo-controlled crossover study

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

A double-blind, randomized, placebo-controlled, two-period crossover study in healthy male subjects.